Last $2.78 USD
Change Today -0.216 / -7.20%
Volume 1.8K
CCEL On Other Exchanges
Symbol
Exchange
OTC US
As of 1:31 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

cryo-cell intl inc (CCEL) Snapshot

Open
$2.82
Previous Close
$3.00
Day High
$2.85
Day Low
$2.54
52 Week High
10/1/14 - $3.50
52 Week Low
01/9/14 - $1.82
Market Cap
27.2M
Average Volume 10 Days
4.0K
EPS TTM
$0.02
Shares Outstanding
9.8M
EX-Date
--
P/E TM
113.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for CRYO-CELL INTL INC (CCEL)

Related News

No related news articles were found.

cryo-cell intl inc (CCEL) Related Businessweek News

No Related Businessweek News Found

cryo-cell intl inc (CCEL) Details

Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. The company offers advanced cord tissue service, which stores a section of the umbilical cord tissue, which is a source of mesenchymal stem cells that are used in regenerative medicine research targeting potential therapies for a range of conditions, including heart disease, stroke, multiple sclerosis, and diabetes; and reproductive tissue storage service for cryopreserved embryos, oocytes, and sperm that offers reproductive tissue services, including short and longer-term cryogenic storage, inter-facility transportation coordination, and special quarantined cryogenic storage for infectious disease positive specimens. It stores approximately 300,000 cord blood and cord tissue specimens worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.

74 Employees
Last Reported Date: 02/28/14
Founded in 1989

cryo-cell intl inc (CCEL) Top Compensated Officers

Chairman and Co-Chief Executive Officer
Total Annual Compensation: $272.5K
Co-Chief Executive Officer and Director
Total Annual Compensation: $242.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $187.9K
Chief Information Officer
Total Annual Compensation: $173.4K
Compensation as of Fiscal Year 2013.

cryo-cell intl inc (CCEL) Key Developments

Cryo-Cell International, Inc. Announces Consolidated Earnings Results for the Third Quarter Ended August 31, 2014

Cryo-Cell International, Inc. announced consolidated earnings results for the third quarter ended August 31, 2014. Consolidated revenues for the third quarter of fiscal 2014 were approximately $4.9 million compared to approximately $4.8 million for the third quarter of fiscal 2013. Net income for the three months ended August 31, 2014 of approximately $237,000, or $0.02 per basic and diluted share, compared to net income of approximately $194,000, or $0.02 per basic and diluted share for the three months ended August 31, 2013. The increase in net income for the three months ended August 31, 2014 is partially a result of a 2% increase in revenues and a settlement received from litigation.

Cryo-Cell International, Inc. Amends Bylaws and Added Articles X and XI

Cryo-Cell International, Inc. announced that on September 22, 2014, the Board of Directors of the company amended the company's Bylaws and added Articles X and XI.

Cryo-Cell International, Inc. Announces Consolidated Earnings Results for the Second Quarter Ended May 31, 2014

Cryo-Cell International, Inc. announced consolidated earnings results for the second quarter ended May 31, 2014. Consolidated revenues were approximately $4.9 million compared to approximately $4.9 million for the second quarter of fiscal 2013. Net income was approximately $216,000, or $0.02 per basic and diluted share, compared to a net loss of approximately $244,000, or $0.02 per basic and diluted share for the three months ended May 31, 2013. The increase in net income for the three months ended May 31, 2014 principally resulted from a 1% increase in revenues, and a 7% decrease in selling, general and administrative expenses, partially offset by an 8% increase in cost of sales. The increase in cost of sales is a result of the increase in laboratory costs associated with the processing technology the company began using during the fourth quarter of fiscal 2013. The revenues for the second quarter of fiscal 2014 consisted of approximately $4.7 million in processing and storage fee revenue and approximately $169,000 in licensee income compared to approximately $4.5 million in processing and storage fee revenue and approximately $328,000 in licensee income for the second quarter of fiscal 2013. The 48% decrease in licensee income for the three months ended May 31, 2014 compared to the three months ended May 31, 2013 is the result of decreased licensee income from Cryo-Cell de Mexico as Mexico paid the remaining balance due under the amendment to the license agreement during the first fiscal quarter 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCEL:US $2.78 USD -0.216

CCEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bionet Corp 39.60 TWD +0.45
CryoLife Inc $10.39 USD +0.11
Osiris Therapeutics Inc $14.45 USD +0.12
Smith & Nephew PLC 1,108 GBp +19.00
Vitrolife AB kr158.50 SEK +3.50
View Industry Companies
 

Industry Analysis

CCEL

Industry Average

Valuation CCEL Industry Range
Price/Earnings 46.5x
Price/Sales 1.5x
Price/Book NM Not Meaningful
Price/Cash Flow 34.2x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CRYO-CELL INTL INC, please visit www.cryo-cell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.